Galectin-1 expression in breast cancer stroma - prognostic value in triple-negative breast cancer.

IF 3.5 4区医学 Q3 CELL BIOLOGY

Pathobiology Pub Date : 2025-05-28 DOI:10.1159/000546206

Szintia Almási, Tibor Krenács, László Krenács, Gábor Cserni

{"title":"Galectin-1 expression in breast cancer stroma - prognostic value in triple-negative breast cancer.","authors":"Szintia Almási, Tibor Krenács, László Krenács, Gábor Cserni","doi":"10.1159/000546206","DOIUrl":null,"url":null,"abstract":"Introduction: Galectin-1 is a lectin with immunosuppressive effect in different solid tumors. We investigated galectin-1 expression in triple-negative breast cancer (TNBC) to determine its prognostic value.Methods: We examined 95 TNBC surgical samples in tissue microarrays with galectin-1 immunohistochemistry (intensity and percentage of staining) and looked for influences on overall and progression free survivals with the help of Kaplan-Meier estimates. Univariable and multivariable Cox regressions were also analyzed.Results: According to Kaplan-Meier curves, a significantly worse overall survival (OS) was found for TNBC patients showing intense or ≥50% galectin-1 stromal interface staining versus those lacking it. Cox regression analyses suggested that galectin-1 expression was an independent prognosticator in TNBC. According to the quantity of stromal tumor-infiltrating lymphocytes (sTILs), significant survival differences depending on galectin-1 status were only seen in the low sTILs (<30%) subset. Multivariable analysis suggested that galectin-1 expression was an independent prognosticator for progression-free survival (PFS).Discussion: The immunosuppressive effects of galectin-1 forming a shield around tumor nests may form an immune-escape mechanism and can explain the worse OS and PFS we found in TNBC. Owing to the exploratory nature of the study, the results need confirmation in order to investigate the potentials of anti-galectin-1 therapies.","PeriodicalId":19805,"journal":{"name":"Pathobiology","volume":" ","pages":"1-20"},"PeriodicalIF":3.5000,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathobiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546206","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Galectin-1 is a lectin with immunosuppressive effect in different solid tumors. We investigated galectin-1 expression in triple-negative breast cancer (TNBC) to determine its prognostic value.

Methods: We examined 95 TNBC surgical samples in tissue microarrays with galectin-1 immunohistochemistry (intensity and percentage of staining) and looked for influences on overall and progression free survivals with the help of Kaplan-Meier estimates. Univariable and multivariable Cox regressions were also analyzed.

Results: According to Kaplan-Meier curves, a significantly worse overall survival (OS) was found for TNBC patients showing intense or ≥50% galectin-1 stromal interface staining versus those lacking it. Cox regression analyses suggested that galectin-1 expression was an independent prognosticator in TNBC. According to the quantity of stromal tumor-infiltrating lymphocytes (sTILs), significant survival differences depending on galectin-1 status were only seen in the low sTILs (<30%) subset. Multivariable analysis suggested that galectin-1 expression was an independent prognosticator for progression-free survival (PFS).

Discussion: The immunosuppressive effects of galectin-1 forming a shield around tumor nests may form an immune-escape mechanism and can explain the worse OS and PFS we found in TNBC. Owing to the exploratory nature of the study, the results need confirmation in order to investigate the potentials of anti-galectin-1 therapies.

查看原文本刊更多论文

半凝集素-1在乳腺癌基质中的表达对三阴性乳腺癌的预后价值。

半乳糖凝集素-1是一种在不同实体肿瘤中具有免疫抑制作用的凝集素。我们研究了半凝集素-1在三阴性乳腺癌（TNBC）中的表达，以确定其预后价值。方法：我们用半凝集素-1免疫组化（染色强度和百分比）在组织微阵列中检测了95例TNBC手术样本，并借助Kaplan-Meier估计寻找对总生存率和无进展生存率的影响。单变量和多变量Cox回归分析。结果：根据Kaplan-Meier曲线，与缺乏半乳糖凝集素-1基质界面染色的TNBC患者相比，半乳糖凝集素-1基质界面染色强烈或≥50%的TNBC患者的总生存期（OS）明显更差。Cox回归分析提示，半凝集素-1表达是TNBC的独立预后因素。根据间质肿瘤浸润淋巴细胞（stil）的数量，仅在低stil中观察到取决于半凝集素-1状态的显著生存差异(讨论：半凝集素-1在肿瘤巢周围形成屏障的免疫抑制作用可能形成免疫逃逸机制，可以解释我们在TNBC中发现的更差的OS和PFS。由于该研究的探索性，结果需要确认，以探讨抗半乳糖凝集素-1治疗的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pathobiology 医学-病理学

CiteScore

8.50

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： ''Pathobiology'' offers a valuable platform for the publication of high-quality original research into the mechanisms underlying human disease. Aiming to serve as a bridge between basic biomedical research and clinical medicine, the journal welcomes articles from scientific areas such as pathology, oncology, anatomy, virology, internal medicine, surgery, cell and molecular biology, and immunology. Published bimonthly, ''Pathobiology'' features original research papers and reviews on translational research. The journal offers the possibility to publish proceedings of meetings dedicated to one particular topic.